Molecule
Zinc sulfate is a copper absorption inhibitor indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. MedsAcross supplies Zinc sulfate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Zinc Sulfate Injection is indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Zinc Sulfate Injection is a trace element indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Source: US FDA prescribing information
Zinc is an essential trace element. Zinc functions as a cofactor of various enzymes including DNA polymerases, RNA polymerases, alcohol dehydrogenase, and alkaline phosphatases. Zinc is a coordinator of protein structural folding, such as folding of “Zinc finger” motif that interacts with a variety of proteins, lipids, and nucleic acids. In addition, zinc is a catalyst of essential biochemical reactions, including activation of substrates of carbonic anhydrase in erythrocyte. Also, zinc is a signaling mediator modulating multiple signaling pathways.
Source: US FDA prescribing information
Pharmacy Bulk Package. Not for direct intravenous infusion. See full prescribing information for information on preparation, administration, and general dosing considerations. Recommended Dosage and Monitoring. Zinc Sulfate Injection provides 1 mg/mL, 3 mg/mL or 5 mg/mL of zinc. Zinc Sulfate Injection in a concentration of 1 mg/mL is recommended for use in pediatric patients, particularly those weighing less than 12 kg. Individualize the dosage based upon the patient’s clinical condition, nutritional requirements, and the contribution of oral or enteral zinc intake. o Adults: The recommended adult dosage is 3 mg/day for metabolically stable patients, with potential need for a higher daily dosage in monitored patients with small bowel fluid loss or excess stool or ileostomy output. o Pediatrics: The recommended dosage in pediatric patients is shown by age and estimated weight.
Source: US FDA prescribing information
Zinc Sulfate Injection is contraindicated in patients with known hypersensitivity to zinc Known hypersensitivity to zinc.
Source: US FDA prescribing information
Pulmonary Embolism due to Pulmonary Vascular Precipitates: If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. Vein Damage and Thrombosis: Solutions with osmolarity of 900 mOsmol/L or more must be infused through a central catheter. Aluminum Toxicity: Increase risk in patients with renal impairment, including preterm infants. Monitoring and Laboratory Tests: Monitor fluid and electrolyte status, serum osmolarity, blood glucose, liver and kidney function, blood count and coagulation parameters throughout treatment. Copper Deficiency: If signs and symptoms develop, interrupt treatment with Zinc Sulfate Injection and check zinc, copper, and ceruloplasmin levels. Hypersensitivity Reactions: If reactions occur, discontinue Zinc Sulfate Injection and initiate appropriate medical treatment.
Source: US FDA prescribing information
No zinc-related adverse reactions have been reported in clinical studies or post-marketing reports in patients receiving intravenously administered parenteral nutrition solutions containing zinc sulfate within the recommended dosage range. The following were identified in clinical studies or post-marketing reports.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15° to 30°C (59° to 86°F). For storage of admixed solution see Dosage and Administration.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Zinc sulfate, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Zinc sulfate 25 mg/5 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Zinc sulfate 30 mg/10 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Zinc sulfate 10 mg/10 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 5 May 1987 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 3 presentations of Zinc sulfate and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Zinc sulfate on 5 May 1987, according to Drugs@FDA.
No listed presentation of Zinc sulfate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Zinc sulfate is classified under ATC code A12CB01 (Zinc sulfate).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.